The Impressive Dr. Bernd Seizinger (Director)Bernd Seizinger is an impressive fellow as can be seen from his many achievements and extensive experience. He appears to have become a director at ONC/Y around June of 2015 based on the SEDI insider filings. He began accumulating Oncolytics Biotech common shares in 2018 and his latest and largest share purchase was on June 14, 2022 when he purchased 50,000 shares on the open market at an average price of $0.8613 USD. He now owns a total of 314,863 shares of Ocolytics in addition to his 65,263 options.
The following is from the Aptose Biosciences Inc. website where Dr. Seizinger has recently become a director (September 2022):
Dr. Seizinger is an accomplished executive leader with more than 25 years of industry experience in both U.S. and European biotechnology and pharmaceutical companies and multiple financial advisory positions. He has held numerous senior executive and board positions including with Bristol-Myers Squibb, where he served as VP for oncology drug discovery and VP for corporate and academic alliances. He has served as CEO and President of German biopharmaceutical company GPC Biotech and CSO of Genome Therapeutics and is a Co-founder and currently serves as Executive Chairman/Interim CEO of CryptoMedix. He is Chairman of the Board of Directors for Oxford Biotherapeutics (U.K.) and serves in board positions for Aprea (Sweden), Oncolytics (Canada), Vaccibody (Norway), and BioInvent (Sweden). Prior to his corporate appointments, Dr Seizinger held senior faculty positions at Harvard Medical School and Massachusetts General Hospital and was a Visiting Professor at Princeton University during his tenure at Bristol-Myers Squibb. Dr. Seizinger received his Ph.D. from Max-Planck-Institute of Psychiatry/Neurobiology and his M.D. from Ludwig-Maximilians-Universitt Mnchen.
I notice that on December 12, 2022, which is three months after Dr. Seizinger became a director at Aptose Biosciences, that Aptose Biosciences initiated their own ATM (at-the-market) facility for raising funds through the sale of shares. It appears that an ATM facility is viewed favourably by Dr. Seizinger. It certainly hasn't prevented him from purchasing large numbers of shares in Oncolytics Biotech.